Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02504424Not ApplicableCompleted

AirXpanders AeroForm Tissue Expander System for Breast Reconstruction

Role: lead

NCT01009008Not ApplicableCompleted

Patient Activated Controlled Expansion (PACE) Trial

Role: lead

NCT01425268Not ApplicableCompleted

Patient Controlled Tissue Expansion for Breast Reconstruction

Role: lead

NCT01903174Not ApplicableCompleted

Study of AeroForm Tissue Expander for Breast Reconstruction

Role: lead

All 4 trials loaded